According to a new study, Remdesivir can significantly reduce the risk of hospitalization for high-risk COVID-19 patients.

The antiviral drug was tested on over 500 patients considered high risk due to either their health conditions or age.

It was found that the drug reduced the risk of hospitalization by 87% by day 28 and reduced the risk of dying by 81%.

Remdesivir is currently approved for hospitalized patients 12 and over.